Telomir's Telomir-1 Shows Excellent Safety Profile in Preclinical Studies

Telomir Pharmaceuticals (NASDAQ: TELO), a preclinical-stage biotechnology company, has announced highly promising results from comprehensive IND-enabling Good Laboratory Practice toxicology and safety pharmacology studies for its lead therapeutic candidate, Telomir-1 (Zn-Telomir). The company reported no treatment-related adverse or dose-limiting toxicities across cardiovascular, respiratory, phototoxicity, and repeat-dose evaluations in both rodent and non-rodent models, with Telomir-1 demonstrating excellent tolerability, no concerning cardiac or respiratory safety signals, no phototoxic potential, and only limited, reversible, non-adverse findings in repeated-dose studies. These findings, which also showed consistent systemic exposure and predictable pharmacokinetics following oral administration, represent a significant milestone in the development pathway, supporting continued advancement toward first-in-human clinical trials pending final quality assurance review and regulatory approvals.

Telomir Pharmaceuticals is developing small-molecule therapeutics designed to target the root epigenetic mechanisms underlying cancer, aging, and degenerative diseases, with Telomir-1 demonstrating activity in preclinical studies involving modulation of DNA and histone methylation, restoration of redox balance, and normalization of cellular function. The company's progress is being communicated through specialized platforms like InvestorWire, which provides advanced wire-grade press release syndication as part of the Dynamic Brand Portfolio at IBN, offering access to a vast network of solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution via IBN to millions of followers, and tailored corporate communications solutions to efficiently reach target markets and diverse industries.

For investors and stakeholders following the company's development, the latest news and updates relating to TELO are available in the company's newsroom, while the full press release provides comprehensive details about these critical preclinical safety findings. The successful completion of these IND-enabling studies marks a crucial step forward in Telomir's mission to develop novel therapeutics for some of medicine's most challenging conditions, with the safety profile established in these studies providing a solid foundation for future clinical investigation and potential therapeutic applications in areas of significant unmet medical need.